Photodynamic Therapy in the Treatment of Squamous Cell Carcinoma of the Head and Neck

Photodynamic treatment outcomes of potentially‐malignant lesions and malignancies of the head and neck region: A systematic review

“…had administered oral ALA in three separate doses of 20 mg/kg, at 0, 1, and 2 hours in patients with premalignant and malignant lesions, and the pre‐irradiation time was 2.5 hours after the first dose of ALA to 4 hours. In studies using intravenous administration of PS, the pre‐irradiation time was between 24 and 96 hours compared to 1 between 1 and 5 hours in studies in which PS was applied topically . However, in their study, Shafirstein et al .…”

“…The selected studies were clinical and had a prospective design with a range between two and 147 individuals (Tables and ) . Twelve studies reported a mean age of study participants of between 50 and 67 years (age range: 27‐99 years) . Seventeen studies reported 570 male (range: 1‐93) and 235 female (range: 0‐65) participants .…”

“…Twelve studies reported a mean age of study participants of between 50 and 67 years (age range: 27‐99 years) . Seventeen studies reported 570 male (range: 1‐93) and 235 female (range: 0‐65) participants . Of a total 988 patients from these studies, 534 and 465 had pre‐existing oral PMDS with or without dysplasia and HNSCC, respectively, based on their histopathological examinations …”

“…Twelve studies reported 465 patients with malignant lesions of the head and neck region who were underwent PDT treatment . Twenty‐five studies reported the site of lesions, which included buccal and labial mucosa (maxilla and mandible), tongue, palate, floor of the mouth, buccogingival sulcus, retromolar area, gingiva, and upper and lower alveolus for premalignant lesions, and palate, tongue, alveolus, retromolar area, floor of mouth, buccal mucosa, gingiva, pharynx and larynx, face, neck, maxillary sinus, oropharynx, nasopharynx, parotid gland, tonsil and nose for malignant lesions of the head and neck region . In nine studies, cancer was T 1 stage, whereas in five studies, cancer was T 2 stage .…”

Photodynamic therapy

“…Literature results are reported for 164 patients with primary, recurrent, and metastatic head and neck cancers from 1984-1990 with an overall CR rate of 28% [6]. In our study, 26 patients were treated for squamous cell carcinoma (SCC) of the head and neck from 1985-1989 [9,10]. All patients were administered PF at 2.0 mg kg -1 and treated with 630 nm light from a tunable dye laser at 24 h post-injection.…”